The results indicated that the three candidate biomarkers showed significant differences in the tumor and normal groups in both the training and validation sets; thus, ENTPD1, SERPINA1, and TACSTD2 were all considered candidate biomarkers for PTC for further analysis. The gene discussed is ENTPD1; the disease is neoplasm.